Join the 'Secukinumab' group to help and get support from people like you.
Novartis Receives FDA Approval for Cosentyx (secukinumab) to Treat Patients with Ankylosing Spondylitis and Psoriatic Arthritis
Posted 17 Jan 2016 by Drugs.com
EAST HANOVER, N.J., Jan. 15, 2016 Novartis announced today that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). AS and PsA are both life-long, painful and debilitating inflammatory diseases that affect the joints and/or spine. If not treated effectively, both conditions can lead to irreversible joint and/or spinal bone damage caused by years of inflammation.2,3,4 With these new approvals, Cosentyx is now the first and only interleukin-17A (IL-17A) antagonist approved for AS, as well as moderate to severe plaque psoriasis and PsA, which impacts as many as 30% of patients with psoriasis.5 Cosentyx was approved for adult patients with moderate to severe plaque psoriasis in January 2015 and more than 13,000 patients with this ... Read more
Posted 30 Sep 2015 by Drugs.com
WEDNESDAY, Sept. 30, 2015 – Two experimental drugs show promise in treating psoriasis and a related condition, psoriatic arthritis, new studies report. The drugs, brodalumab and secukinumab (Cosentyx), represent a new approach to treatment, said Michael Siegel, director of research programs at the National Psoriasis Foundation. "These studies show how targeting parts of the immune system can have great effects, and that's really exciting for our patients," said Siegel, who wasn't involved in the research. Psoriasis, a chronic autoimmune condition, causes raised red patches of skin topped with silvery scales. These patches usually appear on the scalp, elbows, knees, face, lower back, hands and feet. Psoriatic arthritis is a form of the disease that includes joint pain, stiffness and swelling. The study findings appear in the Oct. 1 issue of the New England Journal of Medicine. In one ... Read more